Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
One pharmacy director would like to see a lot more comparative data about new therapies.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.
But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.
The Ways In campaign was UnitedHealthcare's first consumer advertising effort.
The multichannel effort — UnitedHealthcare's inaugural consumer brand advertising campaign — launched in March 2015 with the TV commercial Our Song.
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.
Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.
States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.
The drugmaker instead suggested using an economic model it developed.
New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials